|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-4.49/-3.14
|
企業價值
828.20M
|
資產負債 |
每股賬面淨值
6.00
|
現金流量 |
現金流量率
--
|
損益表 |
收益
314.00K
|
每股收益
0.02
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/06/14 00:15 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease. |